Dr Natalia del Campo


My research focuses on the optimisation and application of multi-modal neuroimaging techniques to identify the neurobiological mechanisms underlying psychiatric conditions and associated cognitive deficits. One aspect I am particularly interested in is the contribution of the ascending monoaminergic systems to variability in cognitive performance across individuals. The central study of my doctoral work consisted of the combined use of neuroreceptor positron emission tomography (PET) and magnetic resonance imaging (MRI) to investigate the neural mechanisms underlying attention deficit/hyperactivity disorder (ADHD) and its treatment with methylphenidate (Ritalin), one of the most commonly prescribed medications for ADHD. More recently, my focus of interest has expanded to include other therapeutic areas such as Down's Syndrome and Alzheimer's disease.

Research Focus





[18F] fallypride PET


Clinical conditions

Alzheimer's disease

Attention deficit hyperactivity disorder


Impulsive personality

Obsessive compulsive disorder


Behavioural analysis

Magnetic resonance imaging (MRI)

Neuropsychological testing

Positron Emission Tomography (PET)



Samuel Chamberlain

Roshan Cools

Tim Fryer

Ulrich Muller

Trevor Robbins

Barbara Sahakian


Bruno Vellas Web: http://www.chu-toulouse.fr/-pole-g...

Michael Weiner Web: http://www.adni-info.org/

Associated News Items



    Del Campo N, Fryer TD, Hong YT, Smith R, Brichard L, Acosta-Cabronero J, Chamberlain SR, Tait R, Izquierdo D, Regenthal R, Dowson J, Suckling J, Baron JC, Aigbirhio FI, Robbins TW, Sahakian BJ, Müller U (2013), “A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment.” Brain 136(Pt 11):3252-70 Details


    Del Campo N, Müller U, Sahakian BJ (2012), “Neural and behavioral endophenotypes in ADHD.” Curr Top Behav Neurosci 11:65-91 Details


    Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW (2011), “The Roles of Dopamine and Noradrenaline in the Pathophysiology and Treatment of Attention-Deficit/Hyperactivity Disorder.” Biol Psychiatry Details

    del Campo N, Tait RJ, Acosta-Cabronero J, Hong YT, Izquierdo-Garcia D, Smith R, Aigbirhio FI, Sahakian BJ, Müller U, Robbins TW, Fryer TD (2011), “Quantification of receptor-ligand binding potential in sub-striatal domains using probabilistic and template regions of interest.” Neuroimage 55(1):101-12 Details


    Chamberlain SR, Hampshire A, Müller U, Rubia K, Del Campo N, Craig K, Regenthal R, Suckling J, Roiser JP, Grant JE, Bullmore ET, Robbins TW, Sahakian BJ (2009), “Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study.” Biol Psychiatry 65(7):550-5 Details


    Chamberlain SR, Menzies L, Hampshire A, Suckling J, Fineberg NA, del Campo N, Aitken M, Craig K, Owen AM, Bullmore ET, Robbins TW, Sahakian BJ (2008), “Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives.” Science 321(5887):421-2 Details

    Chamberlain SR, Menzies LA, Fineberg NA, Del Campo N, Suckling J, Craig K, Müller U, Robbins TW, Bullmore ET, Sahakian BJ (2008), “Grey matter abnormalities in trichotillomania: morphometric magnetic resonance imaging study.” Br J Psychiatry 193(3):216-21 Details


    Chamberlain SR, Del Campo N, Dowson J, Müller U, Clark L, Robbins TW, Sahakian BJ (2007), “Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder.” Biol Psychiatry 62(9):977-84 Details

    Menzies L, Achard S, Chamberlain SR, Fineberg N, Chen CH, del Campo N, Sahakian BJ, Robbins TW, Bullmore E (2007), “Neurocognitive endophenotypes of obsessive-compulsive disorder.” Brain 130(Pt 12):3223-36 Details